- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02912169
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease
November 21, 2017 updated by: Ageless Regenerative Institute
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer's Disease
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with Alzheimer's Disease and clinical outcomes?
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF) will be infused intra-venous and Intra nasal.
The therapy is composed of cells derived from a patients' own adipose tissue that are isolated within approximately 1 hour and immediately delivered back to the patient.
Study Type
Interventional
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Aventura, Florida, United States, 33180
- Ageless Regenerative Institute LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
55 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males or females, age 55 or older
- Diagnosis of probable Alzheimer's disease, consistent with criteria from both: 1) National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and 2) Diagnostic and Statistical Manual of Mental Disorders (DSM IV)
- Up to date on all age and gender appropriate cancer screening per American Cancer Society (Refer to section 9.3 for more details).
Exclusion Criteria:
- Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
- Life expectancy < 6 months due to concomitant illnesses.
- Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
- Active infectious disease. For patients who have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM > IgG) and/or syphilis ,then an expert will be consulted as to patient eligibility based on the patient's infectious status
- Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
- Patients on chronic immunosuppressive transplant therapy
- Systolic blood pressure (supine) ≤90 mmHg;
- Resting heart rate > 100 bpm;
- Active clinical infection.
- Cerebrovascular accident within 6 months prior to study entry
- Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
- History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
- Patient or legal guardian if applicable us unwilling and/or not able to give written informed consent.
- Dementia due to any condition other than AD, including vascular dementia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Autologous Adipose-derived Stromal Vascular Fraction infusion
Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
|
Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
Other Names:
IV and Intranasal Infusion of isolated AD-SVF
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Improvement in Mini Mental State Examination (MMSE)
Time Frame: Six months after therapy
|
Improvement in MMSE six months after therapy
|
Six months after therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event
Time Frame: One year after stem cell therapy
|
The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 12-months period following treatment.
|
One year after stem cell therapy
|
Clinical Improvement in Functional Activities Questionnaire (FAQ)
Time Frame: Three and six months after therapy
|
Three and six months after therapy
|
|
Clinical Improvement in Activities of Daily Living Questionnaire (ADL)
Time Frame: Three and six months after therapy
|
Three and six months after therapy
|
|
Clinical Improvement in Geriatric Depression Scale (GDS)
Time Frame: Three and six months after therapy
|
Three and six months after therapy
|
|
Clinical Improvement in Mini Mental State Examination (MMSE)
Time Frame: Three months after therapy
|
Three months after therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2015
Primary Completion (Actual)
November 15, 2017
Study Completion (Actual)
November 15, 2017
Study Registration Dates
First Submitted
April 6, 2016
First Submitted That Met QC Criteria
September 21, 2016
First Posted (Estimate)
September 23, 2016
Study Record Updates
Last Update Posted (Actual)
November 24, 2017
Last Update Submitted That Met QC Criteria
November 21, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD-US-ALZ-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsRecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Liposuction under local anesthesia
-
Erasmus Medical CenterUniversitaire Ziekenhuizen KU Leuven; University of California, San Francisco; Medical Center HaaglandenRecruitingGlioblastomaUnited States, Belgium, Germany, Netherlands, Switzerland
-
Ageless Regenerative InstituteWithdrawnChronic Obstructive Pulmonary DiseaseUnited States
-
Hospital de ViladecansFundacio per la recerca e investigació del Hospital de ViladecansCompleted
-
Pontificia Universidade Catolica de Sao PauloCompletedQuality of Life | Pain, Postoperative | Postoperative Complication | Personal SatisfactionBrazil
-
Astellas Pharma IncCompleted
-
Erasmus Medical CenterMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Brain Neoplasms | Recurrent Glioblastoma | Recurrent Adult Brain Tumor | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme of Brain | Brain Neoplasms, Adult, Malignant | Astrocytoma, Malignant | Brain Neoplasms, AdultUnited States, Germany, Switzerland, Belgium, Netherlands
-
University of Sao PauloCompletedPeriodontal Diseases | Chemotherapy Effect | Mammary Neoplasm, Human
-
UCB PharmaCompleted
-
Centre hospitalier de l'Université de Montréal...Eiffel MedtechNot yet recruiting3D Knee KinematicsCanada
-
Ageless Regenerative InstituteTerminatedOsteoarthritisUnited States